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ABSTRACT
Tuberculosis is one of the leading causes of development of Immune reconstitution inflamma-
tory syndrome (IRIS) in HIV patients receiving antiretroviral therapy (ART). Objective: To 
determine the incidence of IRIS in HIV-TB coinfected patients, and to find out the possible 
risk factors associated with IRIS. Materials and Methods: Study commenced with 96 patients 
adhered to standard antitubercular therapy (ATT) and ART without defaultering, and followed 
up for six months. Result: The mean (± SD) CD4 count and CD4 percentage at baseline was 
59.16 (± 24.63) per mm3 and 4.59% (± 1.73) respectively. Only 18.75% developed IRIS after 
57.05 (± 14.12) days of initiation of ART. Extrapulmonary tuberculosis was the most significant 
factor associated with IRIS (83.33%) than those without IRIS (44.87%) (p = 0.0032). Specifi-
cally, tubercular lymphadenitis (38.88%, p = 0.0364) and disseminated tuberculosis (33.33%, 
p = 0.0217) were significantly associated with IRIS. The other risk factors associated with ap-
pearance of IRIS were higher CD4 count (p = 0.0212) at three months after initiation of ART 
and increment of CD4 count (p = 0.0063) and CD4 percentage (p = 0.0016) during this pe-
riod. The major manifestations of IRIS were fever (40%), followed by lymphadenitis (38%). 
The mortality rate in IRIS was not higher than those without IRIS. Conclusion: Patients with 
extrapulmonary tuberculosis, especially tubercular lymphadenitis, were more likely to develop 
IRIS and fever was associated in most of them. Higher increment of CD4 count may indicate 
development of IRIS in presence of new or worsening tuberculosis lesion.
Keywords: HIV; tuberculosis; immune reconstitution inflammatory syndrome; CD4 lympho-
cyte count.
INTRODUCTION
Human immunodeficiency virus (HIV) in-
fection today is one of the major causes of 
mortality and morbidity globally. Association 
of tuberculosis (TB) coinfection with HIV 
poses greater therapeutic challenge. In devel-
oping nations, patients often present late with 
advanced HIV infection along with different 
opportunistic infections, most commonly 
tuberculosis.1 Tuberculosis in HIV-infected 
patients often presents with diagnostic dif-
ficulties, with increased chance of negative 
sputum smear results, atypical chest 
X-ray findings, negative tuberculin skin 
test, lack of classical granuloma formation 
in late stage and also presence of more fre-
quent extrapulmonary tuberculosis. With 
the advent of highly active antiretrovi-
ral therapy (HAART), incidence rate of im-
mune reconstitution inflammatory syndrome 
(IRIS) also raised significantly. Classically IRIS 
is defined as “occurrence or manifestation of 
new or existing opportunistic infection with-
in six weeks to six months after initiation of 
antiretroviral therapy (ART), with associated 
increase in CD4 count”.2 Any opportunis-
tic infection may present with IRIS though 
tuberculosis (TB) is the major cause. Oth-
er important manifestations include CMV 
retinitis, Pneumocystis jiroveci pneumonia, 
herpes simplex infection, varicella zoster 
virus infection, cryptococcal meningitis, hep-
atitis B, hepatitis C infection and even some 
auto-immune diseases.3 The main features 
of IRIS with TB are increasing pneumonitis, 
development of pleural effusion, occur-
rence of new radiographic lesions, painful 
and enlarged lymphadenopathy, often with 
discharging sinus, persistent fever, develop-
ment of meningitis, expanding intracranial Este é um artigo Open Access sob
 a licença de CC BY-NC-ND
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space occupying lesions etc.4,5 It is hypothesized that 
pro-inflammatory cytokines produced excessively in 
response to systemic bacterial lipopolysacharide, non-
specifically act on latent mycobacterial antigens leading 
to clinical deterioration and paradoxical worsening of 
inflammatory responses.6 In most of the cases, IRIS re-
gress spontaneously without any significant mortality but 
sometimes it may cause worsening clinical scenario with 
respiratory failure and tracheal compression by enlarged 
lymph nodes resulting in death. It should be differentiated 
from exacerbation of tuberculosis due to drug resistance or 
non-compliance, appearance of new tubercular lesion 
or other opportunistic infection due to advancement of 
HIV. Till date, there is lack of clinical data about oc-
currence of IRIS in HIV and TB coinfected patients in 
Indian population. Therefore, we conducted a cross-sectional 
study in a tertiary care set-up to find out prevalence and risk 
factors of IRIS in HIV-TB coinfected patients.
MATERIAL AND METHODS
Recently diagnosed HAART naive HIV-infected pa-
tients, who had clinical, radiological or microbiological 
evidence of active TB, were selected for our study. Inclu-
sion criteria were as follows:
Recently diagnosed HIV positive by ELISA method. 
(According to NACO guideline, a symptomatic sus-
pected HIV-infected person is diagnosed HIV positive 
when the serum sample is reactive with at least two out 
of three different ELISA kit).2 
Patient having active tuberculosis diagnosed by 
clinical features, radiological appearances, presence of 
granuloma in aspiration material, or microscopy and/or 
culture positive acid-fast bacilli (AFB). 
Receiving antitubercular therapy (ATT) from Revised 
National Tuberculosis Control Programme (RNTCP). 
Started ART after 15 days of ATT as per protocol fol-
lowed in the institution. 
All the patients were followed up for the period of six 
months. The patients with non-compliance with either 
ATT or ART during the follow-up period were excluded 
from the study. The diagnosis of IRIS was done using the 
pre-set criteria as follows:
The patient had to be on ART with rising CD4 count.
Prior to starting ART, the patient must have docu-
mented radiological, histological or microbiologically 
confirmed tuberculosis.
Prior to starting ART, patient must have improve-
ment of tuberculosis by antitubercular therapy.
Following initiation of ART, the patients must have 
appearance of new symptoms or re-appearance of previ-
ous symptoms.
The patients must have spontaneous resolution of 
symptoms with continuation of same treatment. 
Our primary objective was to determine the incidence of 
IRIS in HIV-TB coinfected patients. Secondarily we tried to 
find out the possible risk factors for emergence of IRIS. The 
patients were divided into two groups according to develop-
ment of IRIS or not. The demographic, clinical features, site of 
tuberculosis, presence of other opportunistic infection, base-
line and follow-up CD4 count were measured and compared 
between the two groups. The statistical analysis was done, 
using chi-square test and Student’s t test using SPSS ver-16 to 
determine the significance of the variables. A p-value < 0.05 
was taken to be statistically significant. A total of 96 patients, 
who were attending Medicine outdoor and indoor of Medical 
College Kolkata from May 2009 to April 2010, who met the 
eligibility criteria, were included in this study. The study was 
approved by the institutional ethical committee. The neces-
sary informed consent was taken from all the patients. 
RESULTS
Out of 96 patients suffering from both HIV and tubercu-
losis, 84 (87.5%) of them male, only 18 (18.75%) patients 
developed IRIS (Table 1). The initial mean (± SD) CD4 count 
of these patients was 59.16 (± 24.63) per mm3 and initial mean 
CD4 percentage was 4.59% (± 1.73). The baseline parameters 
of the patients developing IRIS and those who did not develop 
IRIS were compared (Table 1). The male:female ratios of both 
groups were comparable. There was no significant difference 
between the two groups in respect of mode of transmission of 
HIV. But the distribution of tuberculosis is strikingly differ-
ent between the two groups. Those, who developed IRIS had 
significantly higher incidence of extrapulmonary tuberculo-
sis (83.33%) than those who did not develop IRIS (44.87%) 
(p = 0.0032). Of the various forms of extrapulmonary tu-
berculosis in IRIS positive patients, most had tubercular 
lymphadenitis (38.88%). None of the IRIS positive pa-
tient had CNS tuberculosis. The initial CD4 count in both 
groups were comparable, but the patients with IRIS experi-
enced significantly higher increments of mean CD4 count 
(45.22 ± 18.17 per mm3) than those without IRIS 
(31.37 ± 14.88 per mm3), and this was statistically significant 
(p = 0.0063) (Table 1). Also after three months, the mean CD4 
count in patients with IRIS (105.56 ± 23.76 per mm3) were 
significantly higher than those without IRIS (90.26 ± 24.23 
per mm3) (p = 0.0212). The symptoms during development of 
IRIS are described in Table 2 and Table 3. Among the various 
systemic symptoms developed with IRIS, fever was predomi-
nant involving 40% patients of IRIS. The second most common 
symptom was generalized lymphadenopathy (38%). The 
incidence of flare up of pulmonary tuberculosis was 18%, 
while that of abdominal tuberculosis manifested by tubercular 
ascites and enlargement of abdominal lymph nodes was 27 
percent. Only five patients required hospital admission for the 
severe manifestation of IRIS and intra-venous hydrocortisone 
was administered as a life-saving measure. Two of them died 
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Table 1. Baseline characteristics of all HIV-TB coinfected patients
  IRIs pos Iris neg p value Total 
  (n = 18) (n = 78)  (n = 96)
Sex   
 Male 16 (88.88%) 68 (87.18%) 0.8433 84 (87.5%)
 Female 2 (11.12%) 10 (12.82%)  12 (12.5%)
Mode of infection    
 Sexual 16 (88.88%) 72 (92.31%) 0.6362 88 (91.67%)
 Blood transfusion 2 (11.12%) 6 (7.69%)  8 (8.33%)
Site of tuberculosis    
 Pulmonary TB 3 (16.66%) 43 (55.13%) 0.0032 46 (47.92 %)
 Extrapulmonary TB 15 (83.33%) 35 (44.87%) 0.0032 50 (52.08 %)
 TB lymphadenitis 7 (38.88%) 13 (16.67%) 0.0364 20 (20.83%)
 Abdominal TB 2 (11.12%) 8 (10.26%) 0.5374 10 (10.42%)
 CNS TB 0 (0%) 5 (6.41%) 0.8926 5 (5.21%)
 Disseminated TB 6 (33.33%) 9 (11.54%) 0.0217 15 (15.625%)
CD4 counts    
 CD4 baseline 60.33 ± 24.13 58.88 ± 24.89 0.8213 59.16 ± 24.63
 CD4 % baseline 4.59 ± 1.64 4.59 ± 1.76 0.9938 4.59 ± 1.73
 CD4 after 3 months 105.56 ± 23.76 90.26 ± 24.23 0.0212 93.13 ± 24.76
 CD4 % after 3 months 8.67 ± 2.28 7.01 ± 1.99 0.0091 7.33 ± 2.14
 CD4 increments 45.22 ± 18.17 31.37 ± 14.88 0.0063 33.97 ± 16.37
 CD4 % increments 4.08 ± 1.85 2.42 ± 1.20 0.0016 2.73 ± 1.49
Death rate 2 (11.11%) 7 (8.97%) 0.3896 9 (9.375%)
Table 2. Distribution of symptoms in the patients of 
TB-IRIS
symptoms during development of IRIs  Frequency
Fever 7 (38.89 %)
 Fever with cough & expectoration 1 (5.56 %)
 Fever with cough & haemoptysis 1 (5.56 %)
 Fever with ascites 2 (11.11 %)
 Fever with lymph node enlargement 2 (11.11 %)
 Fever only 1 (5.56 %)
Cough & expectoration only 1 (5.56 %)
Abdominal lymphadenopathy only 3 (16.67 %)
Lymph node enlargement only 7 (38.89 %)
Total  18
Mean duration of development of IRIS  57.05 ± 14.12
in hospital. ART was continued in all of the patients. The pa-
tients who did not develop IRIS mostly improved clinically 
with resolution of their symptoms. Only 11 of 78 non-IRIS 
patients (14.1%) had clinical deterioration, of which 
three had pulmonary tuberculosis, and the others had 
extrapulmonary tuberculosis. These patients did not show 
any initial improvement. The mortality rates in both TB-IRIS 
and non-IRIS groups were comparable. The cause of death 
in one of the two persons suffering from IRIS was the com-
pression of trachea by enlarged cervical lymph nodes, while 
the other died due to disseminated tuberculosis leading to 
multi-organ failure. Out of seven non-IRIS patients who died 
during the study, three had CNS tuberculosis, mostly men-
ingitis, and four had disseminated tuberculosis. None of the 
patient with pulmonary tuberculosis died during the study. 
The mean duration of development of IRIS after initiation of 
ART was 57.05 (± 14.12) days (Table 2). The ART followed 
was according to the NACO guideline and was similar in both 
groups. ART was started in all patients after 15 days of ATT.
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DISCUSSION
The incidence of IRIS varies throughout the world. In pre-
HAART era, incidence of IRIS in developed countries was 
reported to be about 36%.7 In developing countries, due to 
higher prevalence of tuberculosis, the incidence of IRIS is 
also higher, though remains largely under reported. The in-
cidence in developing countries ranges from 11% to 43%, 
whereas in India it was reported as 8%.6,8 In our study, 
incidence of TB-IRIS was 18.75%. As HAART is now 
widely available in India, the incidence of IRIS is like-
ly to be increasing. The IRIS appears mostly within first 
three months of initiating ART. In our study the mean 
duration of appearance of IRIS was 57.05 days. The early 
appearance of IRIS may be due to early initiation of ART, 
after 15 days of ATT, in all patients. Other studies from 
developing countries like Brazil also documented simi-
lar result.9 Shelburne et al.10 showed that IRIS is more 
likely to develop earlier if HAART is initiated earlier.
Most of the IRIS patients experienced an exacerbation of 
extrapulmonary tuberculosis, tubercular lymphadenitis 
being most common. Significantly 27% of the patients pre-
sented with intra-abdominal flaring up of tuberculosis. 
Various previous studies also showed similar result though 
occurrence of intra- abdominal tuberculosis was not high.11-13 
This highlights that one must look out for the enlargement 
of abdominal lymph nodes as a marker of IRIS. Interestingly, 
in our study, none had CNS tubercular manifestation. This 
may be because CNS involvement in TB-IRIS usually oc-
curs late with median interval being 5-10 months.14 The risk 
factor emerged from the study was presence of extrapulmo-
nary tuberculosis, of which tubercular lymphadenitis and 
disseminated tuberculosis predominates. These findings 
corroborates with the findings of previous western studies, 
though they did not show disseminated tuberculosis as a risk 
factor.15 This may be due to the fact, that exposure to high 
load of mycobacterium and their interaction with the im-
mune system in disseminated form of tuberculosis increases 
the risk of IRIS.16 The baseline CD4 count was not a risk 
factor for emergence of IRIS. Although previous studies, 
including those from different developing countries with 
high prevalence of HIV, postulated that CD4 counts less 
than 100 per mm3 are associated with increased incidence 
of IRIS, this was not present in our study.9,17 Rather, the in-
crease in absolute as well as percentage of CD4 count was 
significantly higher in IRIS group of patients than the other. 
Similar result was shown by Breton G et al.12 This may be due 
to the inherent pathophysiology of IRIS development. With 
the initiation of ART, there is partial restoration of immune 
response, which causes increase in CD4 count. As IRIS 
occurs due to excessive effect of various inflammatory me-
diators liberated from activated lymphocytes, so increment 
of CD4 count is related with occurrence of IRIS and it may 
act as a surrogate marker of development of IRIS, though 
more detailed studies need to be done to know the actual 
predictive value. The major limitation of the study was 
exclusion of subclinical tuberculosis patients who may 
develop IRIS after initiation of ART. Also all the patients 
were given standard ATT and ART, so effect of variation 
of therapy with emergence of IRIS was not evaluated. 
In addition, because ART was started after 15 days of ATT 
in all patients, any effect of delay of ART with appearance 
of IRIS could not be studied. All the patients recruited in 
the study were in advanced HIV. Further study is needed 
to know the variation of incidence of IRIS at different 
stages of HIV. Although most of our patients recovered 
spontaneously without requiring any deviation from their 
treatment protocol, large prospective study will guide us 
about proper management of IRIS.
CONCLUSION
In conclusion, IRIS in HIV-TB coinfected patients is an 
important entity, 12% of the patients developed IRIS in 
our study within two months of starting ART. Patients 
with extrapulmonary tuberculosis, especially tubercular 
lymphadenitis are more prone to develop IRIS. Fever is 
associated in most of these patients. Higher increment of 
CD4 count may give warning for development of IRIS in 
presence of new or worsening tuberculosis lesion.
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